Jaguar Health Reports Promising Results for Crofelemer in Rare Pediatric Intestinal Failure Conditions

Jaguar Health查看公司主页's subsidiary Napo Pharmaceuticals (搜索)搜索该词条 announced the acceptance of two late-breaking abstracts for presentation at the 58th Annual Meeting of ESPGHAN, showcasing promising results for liquid oral crofelemer查看药品详情 in treating pediatric intestinal failure (搜索)搜索该疾病 (IF) caused by microvillus inclusion disease (搜索)搜索该疾病 (MVID) and short bowel syndrome (搜索)搜索该疾病 (SBS). The data represents significant progress for patients with these ultrarare conditions who currently depend on life-sustaining parenteral support.

Clinical Trial Results Show Reduced Parenteral Support Needs

The abstracts detail outcomes from two separate investigator-initiated trials involving pediatric IF patients receiving crofelemer查看药品详情 as adjunctive therapy. One infant MVID patient has been treated with crofelemer alongside parenteral support for more than six months, while other pediatric patients with IF due to MVID and/or SBS received crofelemer adjunctive therapy for over one year with reduced amounts of parenteral support.

According to Dr. Pravin Chaturvedi, Napo's Chief Scientific Officer and Chair of the company's Scientific Advisory Board, "Crofelemer查看药品详情 has demonstrated reductions in parenteral support needs for IF patients with both MVID and SBS. Crofelemer has been well tolerated, and the pediatric IF patients are gaining weight and height, demonstrating reductions in their needs for PS, especially when adjusted for body weight."

Addressing Critical Unmet Medical Need

MVID represents a congenital enteropathy with a lethal natural history if not treated with life-sustaining and lifelong total parenteral nutrition (TPN) with or without supplemental intravenous fluids. The condition is estimated to have a prevalence of approximately 200 patients globally. According to the company, crofelemer查看药品详情 is currently being used to treat approximately 4% of the prevalent MVID patients, including additional patients enrolled in an ongoing blinded study.

The reduction in parenteral support needs carries significant clinical implications, as TPN is associated with serious toxicities including life-threatening infections, metabolic complications, liver and kidney function problems, reduction in normal growth parameters, and cognitive functioning impacts. Many intestinal failure (搜索)搜索该疾病 patients require parenteral support up to seven days a week, sometimes for 20 hours or more per day.

Regulatory Progress and Development Pipeline

Jaguar has received orphan drug designations for both MVID and SBS in the United States and European Union. The company has completed enrollment of pediatric MVID patients in an ongoing randomized clinical trial with plans for a New Drug Application (NDA) filing in mid-2027.

Lisa Conte, the company's founder and CEO, emphasized the drug's safety profile: "Crofelemer查看药品详情 continues to have an impressive safety profile while demonstrating disease progression modification for the fragile pediatric IF patient population. The company has received interest and support from the parents of these IF patients, which has been heartening and inspirational."

Expanding Clinical Development

Beyond the pediatric studies, Jaguar's family company Napo Therapeutics (搜索)搜索该词条 S.P.A. is continuing to enroll adult patients with IF due to SBS using the same formulation of crofelemer查看药品详情. This randomized double-blind placebo-controlled trial is being conducted at multiple sites in Germany and Italy. An investigational study in adult SBS-IF patients is also being partially supported by the company in the United States.

The clinical development program represents a comprehensive approach to addressing intestinal failure (搜索)搜索该疾病 across different patient populations and underlying conditions, with crofelemer查看药品详情 positioned as a potential adjunctive therapy to reduce dependence on parenteral support while maintaining patient safety and promoting normal growth parameters.